These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 32906027)

  • 1. Risk of malignancy with non-TNFi biologic or tofacitinib therapy in rheumatoid arthritis: A meta-analysis of observational studies.
    Xie W; Yang X; Huang H; Gao D; Ji L; Zhang Z
    Semin Arthritis Rheum; 2020 Oct; 50(5):930-937. PubMed ID: 32906027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Risk of Cardiovascular Events With Biologic and Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.
    Singh S; Fumery M; Singh AG; Singh N; Prokop LJ; Dulai PS; Sandborn WJ; Curtis JR
    Arthritis Care Res (Hoboken); 2020 Apr; 72(4):561-576. PubMed ID: 30875456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A meta-analysis of biologic therapies on risk of new or recurrent cancer in patients with rheumatoid arthritis and a prior malignancy.
    Xie W; Xiao S; Huang Y; Sun X; Gao D; Ji L; Li G; Zhang Z
    Rheumatology (Oxford); 2020 May; 59(5):930-939. PubMed ID: 31620795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments.
    Xie F; Yun H; Bernatsky S; Curtis JR
    Arthritis Rheumatol; 2016 Nov; 68(11):2612-2617. PubMed ID: 27213279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland.
    Finckh A; Tellenbach C; Herzog L; Scherer A; Moeller B; Ciurea A; von Muehlenen I; Gabay C; Kyburz D; Brulhart L; Müller R; Hasler P; Zufferey P;
    RMD Open; 2020 May; 6(1):. PubMed ID: 32385143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of discontinuation rates of tofacitinib and biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis: a systematic review and Bayesian network meta-analysis.
    Park SK; Lee MY; Jang EJ; Kim HL; Ha DM; Lee EK
    Clin Exp Rheumatol; 2017; 35(4):689-699. PubMed ID: 28079510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis.
    Vieira MC; Zwillich SH; Jansen JP; Smiechowski B; Spurden D; Wallenstein GV
    Clin Ther; 2016 Dec; 38(12):2628-2641.e5. PubMed ID: 27889300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled trials.
    Lee YH; Bae SC
    Int J Rheum Dis; 2016 Nov; 19(11):1103-1111. PubMed ID: 26692536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
    Wadström H; Frisell T; Askling J;
    JAMA Intern Med; 2017 Nov; 177(11):1605-1612. PubMed ID: 28975211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of malignancy associated with use of tocilizumab versus other biologics in patients with rheumatoid arthritis: A multi-database cohort study.
    Kim SC; Pawar A; Desai RJ; Solomon DH; Gale S; Bao M; Sarsour K; Schneeweiss S
    Semin Arthritis Rheum; 2019 Oct; 49(2):222-228. PubMed ID: 30967248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative risk of osteoporotic fracture among patients with rheumatoid arthritis receiving TNF inhibitors versus other biologics: a cohort study.
    Shin A; Park EH; Dong YH; Ha YJ; Lee YJ; Lee EB; Song YW; Kang EH
    Osteoporos Int; 2020 Nov; 31(11):2131-2139. PubMed ID: 32514765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Most Appropriate Conventional Disease-Modifying Antirheumatic Drug to Combine With Different Advanced Therapies in Rheumatoid Arthritis: A Systematic Literature Review With Meta-Analysis.
    Decarriere G; Barnetche T; Combe B; Gaujoux-Viala C; Lukas C; Morel J; Daien C
    Arthritis Care Res (Hoboken); 2021 Jun; 73(6):873-884. PubMed ID: 32216091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study.
    Pawar A; Desai RJ; Solomon DH; Santiago Ortiz AJ; Gale S; Bao M; Sarsour K; Schneeweiss S; Kim SC
    Ann Rheum Dis; 2019 Apr; 78(4):456-464. PubMed ID: 30679153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of infection-related hospitalization risk and costs in tumor necrosis factor inhibitor-experienced patients with rheumatoid arthritis (RA) treated with abatacept or other targeted disease-modifying anti-rheumatic drugs (tDMARDs).
    Paul D; Patil D; McDonald L; Patel V; Lobo F
    J Med Econ; 2020 Sep; 23(9):1025-1031. PubMed ID: 32427547
    [No Abstract]   [Full Text] [Related]  

  • 15. Risk of malignancy in patients with rheumatoid arthritis after anti-tumor necrosis factor therapy: results from Korean National Health Insurance claims data.
    Jung SM; Kwok SK; Ju JH; Park YB; Park SH
    Korean J Intern Med; 2019 May; 34(3):669-677. PubMed ID: 29172405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials.
    Strand V; Ahadieh S; French J; Geier J; Krishnaswami S; Menon S; Checchio T; Tensfeldt TG; Hoffman E; Riese R; Boy M; Gómez-Reino JJ
    Arthritis Res Ther; 2015 Dec; 17():362. PubMed ID: 26669566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis.
    Maneiro JR; Souto A; Gomez-Reino JJ
    Semin Arthritis Rheum; 2017 Oct; 47(2):149-156. PubMed ID: 28284845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tofacitinib and Risk of Malignancy: Results From the Safety of Tofacitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA) Study.
    Khosrow-Khavar F; Desai RJ; Lee H; Lee SB; Kim SC
    Arthritis Rheumatol; 2022 Oct; 74(10):1648-1659. PubMed ID: 35643956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: analysis of the Australian Rheumatology Association Database (ARAD) prospective cohort study.
    Buchbinder R; Van Doornum S; Staples M; Lassere M; March L
    BMC Musculoskelet Disord; 2015 Oct; 16():309. PubMed ID: 26481039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis.
    Curtis JR; Xie F; Yun H; Bernatsky S; Winthrop KL
    Ann Rheum Dis; 2016 Oct; 75(10):1843-7. PubMed ID: 27113415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.